The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising an ephedrine component selected from the group consisting of ephedrine, pseudoephedrine and the physiologically acceptable salts thereof, wherein the weight content of the ephedrine component is within the range of from 0.1 to 60 wt.-%, relative to the total weight of the pharmaceutical dosage form.本發明涉及一種藥物劑型，其具有至少300N的斷裂強度並包含選自麻黃鹼、偽麻黃鹼和其生理學上可接受的鹽的麻黃鹼組分，其中相對於所述藥物劑型的總重量計，所述麻黃鹼組分的重量含量在0.1至60wt.%的範圍內。
